Pfizer Inc. $PFE is Goodman Financial Corp’s 7th Largest Position

Goodman Financial Corp lifted its stake in Pfizer Inc. (NYSE:PFE) by 3.4% during the 1st quarter, Holdings Channel reports. The institutional investor owned 642,252 shares of the biopharmaceutical company’s stock after purchasing an additional 21,038 shares during the quarter. Pfizer comprises about 3.1% of Goodman Financial Corp’s holdings, making the stock its 7th biggest position. Goodman Financial Corp’s holdings in Pfizer were worth $18,034,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Bessemer Group Inc. grew its stake in shares of Pfizer by 3,684.3% during the 1st quarter. Bessemer Group Inc. now owns 5,165,091 shares of the biopharmaceutical company’s stock valued at $145,037,000 after acquiring an additional 5,028,603 shares during the period. Avalon Trust Co raised its stake in Pfizer by 103.4% during the 1st quarter. Avalon Trust Co now owns 1,967 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 1,000 shares during the period. Gerald Baker Financial Group LLC purchased a new position in Pfizer during the first quarter valued at approximately $635,000. Independent Financial Group LLC purchased a new position in Pfizer during the first quarter valued at approximately $1,802,000. Finally, Enterprise Financial Services Corp boosted its position in shares of Pfizer by 1.6% in the first quarter. Enterprise Financial Services Corp now owns 25,681 shares of the biopharmaceutical company’s stock worth $721,000 after purchasing an additional 408 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer received FDA approval for a Padcev plus Keytruda regimen in muscle-invasive bladder cancer, expanding use of the combination as a new treatment option and supporting the company’s oncology growth story. Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen
• Positive Sentiment: Analyst commentary remains constructive on Pfizer’s valuation, with some recent coverage suggesting the stock may still offer upside versus Wall Street targets despite recent weakness. Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?
• Neutral Sentiment: Market commentary also says Pfizer’s shares are below key moving averages, reflecting a cautious technical setup as investors weigh fading COVID revenue against pipeline growth, acquisitions, and dividend support. Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
• Neutral Sentiment: Pfizer also faces a new patent dispute, as Arbutus Biopharma filed international lawsuits over lipid nanoparticle technology used in mRNA COVID-19 vaccines. The case adds legal overhang, though the financial impact is still uncertain. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Pfizer suspended sales of Premarin vaginal cream in India due to supply challenges, which could weigh on near-term international product sales and signals execution issues in the supply chain. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges

Pfizer Stock Performance

NYSE:PFE opened at $25.13 on Friday. The company has a market cap of $143.24 billion, a price-to-earnings ratio of 19.19 and a beta of 0.35. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75. The stock’s 50 day simple moving average is $25.22 and its two-hundred day simple moving average is $26.18. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the prior year, the company earned $0.92 EPS. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Wall Street Analyst Weigh In

PFE has been the topic of several recent analyst reports. Bank of America decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. BMO Capital Markets dropped their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday. CICC Research assumed coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target for the company. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.50.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.